التفاصيل البيبلوغرافية
| العنوان: |
Use of Docetaxel for Treating Hepatocellular Carcinoma |
| Document Number: |
20080045584 |
| تاريخ النشر: |
February 21, 2008 |
| Appl. No: |
11/761512 |
| Application Filed: |
June 12, 2007 |
| مستخلص: |
The present invention is based on the finding that docetaxel is significantly more active against hepatocellular carcinoma cells than paclitaxel at concentrations of up to 1 μM. It accordingly provides the use of docetaxel, or a hydrate thereof, in the manufacture of a medicament for use in the treatment of hepatocellular carcinoma. |
| Inventors: |
CHI, Chin-Wen (Taipei, TW); LIN, Heng-Liang (Taipei, TW); LIU, Tsung-Yun (Taipei, TW); LUI, Wing-Yiu (Taipei, TW); CHAU, Gar-Yang (Taipei, TW) |
| Assignees: |
AVENTIS PHARMA S.A. (Antony, FR) |
| Claim: |
1. A pharmaceutical composition comprising, as an active ingredient, docetaxel in an amount of from 38 to 42 mg/ml. |
| Claim: |
2. A method of treating hepatocellular carcinoma, said method comprising administering to a patient docetaxel in an amount sufficient to treat said hepatocellular carcinoma. |
| Claim: |
3. The method of claim 2, wherein said hepatocellular carcinoma is a fibrolamellar variant. |
| Claim: |
4. The method of claim 2, wherein said hepatocellular carcinoma is a mixed hepatocellular cholangiocarcinoma. |
| Claim: |
5. The method of claim 2, wherein administration is intraperitoneal, subcutaneous, intravenous, intramuscular, or intrasternal. |
| Claim: |
6. The method of claim 5, wherein administration is intravenous. |
| Claim: |
7. The method of claim 6, wherein administration is by intravenous infusion. |
| Claim: |
8. The method of claim 2, further comprising treating with at least one chemotherapeutic agent or antineoplastic drug other than docetaxel. |
| Claim: |
9. The method of claim 2, further comprising treating with at least one biological response modifier. |
| Claim: |
10. The method of claim 2, further comprising treating with immunotherapy, radiotherapy, or both. |
| Claim: |
11. The method of claim 2, wherein the patient is a human. |
| Claim: |
12. The method of claim 11, wherein said method comprises administering docetaxel in at least one dose of from 50 to 150 mg/m2. |
| Claim: |
13. The method of claim 12, wherein said method comprises administering docetaxel in at least one dose of from 60 to 100 mg/m2. |
| Claim: |
14. The method of claim 12, wherein said method comprises administering docetaxel or a hydrate of docetaxel in at least one dose of 100 mg/m2. |
| Claim: |
15. The method of claim 2, wherein said method comprises weekly administration until the desired therapeutic effect is obtained. |
| Claim: |
16. The method of claim 2, wherein said method comprises administration every three weeks until the desired therapeutic effect is obtained. |
| Claim: |
17. The method of claim 16, wherein said method comprises intravenously infusing docetaxel at a dose of 100 mg/m2 over 1 hour every three weeks until the desired therapeutic effect is obtained. |
| Current U.S. Class: |
514449/000 |
| Current International Class: |
61; 61 |
| رقم الانضمام: |
edspap.20080045584 |
| قاعدة البيانات: |
USPTO Patent Applications |
